INTRODUCTION
An infection with high-risk human papillomavirus (hrHPV) is essential for the development of cervical cancer 1, 2 . HrHPV DNA testing has emerged as a more sensitive screening tool than cytology, leading to a higher protection against cervical intraepithelial neoplasia grade 3 (CIN3) and cervical cancer [3] [4] [5] . However, many hrHPV infections have an indolent nature and only a fraction of hrHPV-positive women have high-grade CIN lesions with a high cancer progression risk. In order to reduce overdiagnosis and unnecessary referral, additional triage testing is required to detect the subgroup of hrHPV-positive women with clinically meaningful cervical disease. To date, various triage strategies for hrHPV-positive women have been considered including repeat cytology testing 6 , HPV E7 mRNA analysis 7, 8 , p16/ki67 cytological dual staining 9, 10 , HPV16/18 genotyping 11, 12 , and combinations thereof 6, 13 . Besides these markers, epigenetic changes in the host and/or viral genome that are associated with progression towards invasive cancer 1, 14 are attractive targets to design objective and molecular biomarkers to detect amongst hrHPV-positive women those who have cervical (pre)cancer. DNA methylation analysis of human genes by (quantitative) methylation-specific PCR (MSP)-based methods has shown promising results on both hrHPV-positive cervical scrapes and self-collected specimens [15] [16] [17] [18] [19] [20] , with overall sensitivities for ≥CIN3 similar to those of cytology, and extremely high sensitivities (up to 100%) for cervical carcinoma 16, 18, 21 . When applied to cervical scrapes, a methylation marker recently identified by a genome-wide methylation screen, FAM19A4 22 , was shown to detect all cervical carcinomas and CIN3 lesions with a long-term (i.e., ≥5 years) duration of preceding hrHPV-infection (PHI, used as a proxy of duration of lesion existence) 23 . The latter are considered the more advanced CIN3 lesions with a high short-term progression risk to cancer, partially explained by a high number of chromosomal alterations 24 . As such, FAM19A4 can be an attractive marker for cervical disease in hrHPV-positive women. In this prospective cohort study, performed on hrHPV-positive women from six outpatient clinics, we compared the clinical performance of FAM19A4 methylation analysis to cytology and HPV16/18 genotyping, separately and in combination, for the detection of CIN3 or cervical cancer (≥CIN3).
MATERIALS AND METHODS

Study design, participants, and procedures
From December 2010 till December 2013, women between 18 and 70 years were recruited for participation in a prospective observational multi-center cohort study among women visiting a gynecological outpatient clinic in one of six hospitals in the Netherlands: VU University Medical Center (VUmc), Sint Lucas Andreas Hospital, University Medical Center Utrecht, Reinier de Graaf Groep, Sint Antonius Hospital and Flevo Hospital. The study was approved by the Medical Ethical Committee of all participating hospitals (METc-VUmc2009/178) and registered as NTR2447. Women were eligible for participation in the study regardless of their reason for visiting the gynecologist. Consequently, also women who had been referred because of a recent abnormal cervical scrape could participate. Exclusion criteria included any history of treatment for cervical dysplasia or cervical cancer, current cancer, pregnancy or lactation. As shown in Figure 1 , in total 2970 women gave informed consent and participated in the study. These women were offered self-sampling of cervico-vaginal lavage material using the Delphi screener (Delphi Bioscience, the Netherlands) for hrHPV testing using GP5+/6+ PCR-enzyme immunoassay analysis (EIA kit HPV GP HR, Diassay B.V., the Netherlands) 18 . All self-sample analyses were performed at the department of Pathology at VUmc. From 717 women who tested hrHPV-positive on selfcollected material, 78 (11%) had to be excluded as they did not meet the inclusion criteria. From the remaining 639 women, a cervical scrape was taken by the gynecologist using a Cervex-Brush (Rovers Medical Devices B.V., the Netherlands) or a Medscand Cytobrush Plus (CooperSurgical Inc., USA). Material was stored in 20 ml of Thinprep PreservCyt solution (Hologic, USA). Cervical scrapes that tested hrHPVpositive (n=556) were subsequently tested for three markers: (liquid based) cytology, FAM19A4 methylation and HPV16/18 genotyping. Women with valid test results in all three assays (n=508) comprised the final study population and all underwent colposcopy-examination. In 289 (57%) women, the cervical scrape was taken at a separate visit, at a minimum of two weeks prior to colposcopy. In 219 (43%) women, for logistic reasons, the cervical scrape was done immediately prior to colposcopy. At colposcopy, cervical biopsies were taken from every visible lesion for histological assessment and classified as normal (CIN0), CIN1, CIN2, CIN3, or invasive cancer, according to international criteria. In case no lesions were visible, it was mandatory to take two random biopsies (6 and 12 o' clock). In case the squamocolumnar junction could not be brought into view, endocervical curettage was performed. All women were treated according to national guidelines for CIN and cervical cancer. All women with histologically confirmed CIN3 underwent large loop excision of the transformation zone (LLETZ) or cervical conisation. Depending on the size of the lesion, also 65% (i.e., 65/100) of women with CIN2 underwent LLETZ. Of these, 10 (15%) were diagnosed with CIN3 in the LLETZ tissue, and categorized accordingly.
Cytology
Liquid based cytology preparations were cytologically classified according to the CISOE-A classification (reporting on composition, inflammation, squamous, other and endometrium, and endocervical cylindrical epithelium, and adequacy) used in the Netherlands. The results can be translated into the Bethesda classification 25 , in which borderline or mild dyskaryosis (BMD) equals ASC-US/ASC-H/LSIL, and >BMD equals high-grade squamous intraepithelial lesion (HSIL). Cytotechnicians were aware of the hrHPV-positive status of the cervical scrapes.
HPV genotyping
DNA was isolated from 1/10 th of cervical scrape material using the Nucleo-Spin 96
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, Germany) according to manufacturers' instructions 16 , and subjected to GP5+/6+PCR-EIA. Subsequent genotyping for the high-risk HPV types 16/18/31/33/35/39/45/51/52/56/58/59/66/68 was performed using a microsphere beadbased assay (Luminex) as previously described 26 .
qMSP analysis
Extracted DNA from hrHPV-positive cervical scrapes was subjected to bisulphite treatment using the EZ DNA Methylation Kit (Zymo Research, USA) as described previously 27, 28 . Bisulphite-converted DNA was used as template for FAM19A4 methylation analysis by qMSP using housekeeping gene β-actin (ACTB) as a reference gene 22, 23 . qMSP analysis was performed on an ABI 7500 real-time PCR-system (Applied Biosystems, USA). For each target, Quantification Cycle (Cq) values were measured at a fixed fluorescence threshold. All samples included in the study had a Cq value for ACTB <32 to assure sample quality. For each sample Cq ratios were calculated using the following formula: 2
[Cq (ACTB) -Ct (FAM19A4)] x100. The threshold value (0.415) that gave rise to a ≥CIN3 specificity of 70%, as determined and validated in De Strooper et al. 23 , was chosen to consider a specimen positive for FAM19A4 methylation.
Statistical analysis
We used histologically confirmed ≥CIN3 as primary study endpoint. ≥CIN2 was used as secondary study endpoint, as the category of CIN2 reflects heterogeneous disease, of which a substantial portion represent productive hrHPV-infections 1 that will regress spontaneously 29, 30 . Study endpoint was assessed based on the histological outcome of the colposcopy-directed biopsy, or, if classified worse, on the histology result of the specimen excised by LLETZ, conisation or uterus extirpation. The sample size was set such that 90% power was achieved for demonstrating non-inferiority of FAM19A4 methylation analysis or HPV16/18 genotyping compared to cytology using a matchedsample score test 31, 32 . A minimum of 300 hrHPV-positive women needed to be included at rejection rate α of 0.05. Finally, 508 hrHPV-positive women were included with results for all markers. For FAM19A4 methylation analysis, cytology, HPV16/18 genotyping and combinations (i.e., FAM19A4 and cytology, FAM19A4 and HPV16/18 genotyping, HPV16/18 genotyping and cytology), sensitivity, specificity, positive predictive value (PPV), 1-negative predictive value (complemented NPV, a measure of disease risk after a negative result) for detection of ≥CIN3 and ≥CIN2 and referral rate (based on % marker positivity) were calculated with 95% confidence intervals (95% CI). Relative sensitivities (ratios of the sensitivity of one test to the sensitivity of another test) and relative specificities (ratios of the specificity of one test to the specificity of another test) were calculated with 95% CIs to enable comparisons. A difference in sensitivity or specificity was considered significant if the 95%CI of the relative sensitivity or specificity was entirely below or above one. Forest plots of relative sensitivities and specificities of the different tests were made using cytology as reference test. In case of non-significant differences in sensitivity, an additional non-inferiority test was performed. Non-inferiority was defined as a relative sensitivity of at least 90% using a matched-sample score test 31, 32 . We considered the influence of three factors when estimating the sensitivity and specificity of the different markers. First, the age of the participants (aged ≥30 years (cervical screening target in the Netherlands) versus <30 years); secondly, the reason of referral to the gynecologist (non-cervix-related gynecological complaints versus a recent abnormal cytology result in cervical screening); and thirdly, the sampling method of the cervical scrape (whether the collection of the cervical scrape was done during a separate visit prior to colposcopy versus cervical scrape combined with the colposcopy procedure in one visit). The influence of the factors was studied using logistic regression. After determining the factors that significantly influenced the performance of the different markers (significance: p<0.05), data were stratified for these factors. All statistical analyses and computation of graphs were performed in IBM SPSS Statistics 20, STATA 11.0 and Excel.
RESULTS
Patients and histological outcomes
The study flowchart is shown in Figure 1 . Final analysis comprised 508 women who had valid results for all three markers and who underwent colposcopy-examination. Histology revealed that three women (0.6%) had invasive cervical carcinoma (i.e., one squamous cell carcinoma (SCC), one adenosquamous carcinoma and one adenocarcinoma (AdCA)), 87 women (17.1%) had CIN3 (including 2 adenocarinoma in situ), 90 women (17.7%) had CIN2, 138 (27.2%) had CIN1 and 190 (37.4%) had no CIN. Of the corresponding 508 hrHPV-positive cervical scrapes, 37% (189/508) scored positive for FAM19A4 methylation, 56% (287/508) had abnormal cytology (≥BMD) and 48% (243/508) tested positive for HPV16 and/or HPV18 (HPV16/18). All three women diagnosed with cervical cancer tested positive for both FAM19A4 methylation and cytology. Two of them scored HPV16 positive, and one woman with SCC had a single infection with HPV39.
Performance of markers
Test specifications of the investigated markers, and combinations thereof, for detection of ≥CIN3 in the total study population are shown in Table 1 (upper panel) . Relative sensitivities and specificities for ≥CIN3 of FAM19A4 methylation analysis, HPV16/18 genotyping, and various marker combinations compared to cytology (which was used as reference), are shown in Figure 2 (upper panel). The ≥CIN3 sensitivity of FAM19A4 methylation analysis (75.6%) and cytology (85.6%) did not differ significantly. As a statistical difference between the sensitivities of both markers could not be established, subsequent matched sample score testing was performed to evaluate non-inferiority. As the relative sensitivity of FAM19A4 methylation analysis was lower than 90%, the noninferiority threshold was not met (p=0.61). The ≥CIN3 specificity (71.1%) of FAM19A4 methylation analysis was significantly higher than that of cytology (49.8%). For ≥CIN2 outcome (Table 2 and Figure 3, Table  2 ). The ≥CIN3 sensitivity of FAM19A4 methylation analysis combined with cytology was significantly higher than that of cytology alone (94.4% versus 85.6%), but had a significantly lower specificity (37.8% versus 49.8%; Table 1; Figure 2 ). The ≥CIN3 sensitivity of combined FAM19A4 methylation analysis and HPV16/18 genotyping was non-inferior to cytology (92.2% versus 85.6%; p<0.001) but had a significantly lower specificity (42.3% versus 49.8%; Table 1; Figure 2 ).
Factors influencing marker performance
Three factors were evaluated for a potential influence on marker performance: 1) age of the participants , i.e., women ≥30 years (n=287) or <30 years (n=221); 2) reason of referral, i.e., because of a recent abnormal cytological scrape (n=213) or non-cervixrelated gynecological complaints (n=295), 3) moment of taking cervical scrape, i.e., at a separate visit 2-3 weeks prior to the colposcopy visit (n=289) or at the same visit as colposcopy (n=219). The performance of FAM19A4 methylation analysis was significantly influenced by age of the participants (Table 3A) , whereas the performance of cytology was significantly correlated to the referral reason to the gynecologist, both in univariate and multivariate analyses (Table 3B ). The performance of HPV16/18 genotyping was not influenced by any of these variables (data not shown). The moment of taking the cervical scrape did not influence the performance of the investigated markers.
Stratified analysis of marker performance
Subsequently, marker analysis was performed after stratification for age (for FAM19A4 methylation analysis) and referral reason (for cytology). Of note, in women <30 years, 31% was referred based on non-cervix-related complaints whereas in women ≥30 years 56% was referred with an abnormal scrape. The performance of the markers in the subpopulation of women ≥30 years for the detection of ≥CIN3 (n=287; 60 ≥CIN3, 51 CIN2 and 176 ≤CIN1), the age group targeted in Dutch national screening, are shown in Table 1 and Figure 2 (lower panel). In this subpopulation, the ≥CIN3 sensitivity of FAM19A4 methylation analysis (88.3%) was non-inferior (p=0.024) to that of cytology (85.0%), whereas its specificity was significantly higher (62.1% versus 47.6%). Results for ≥CIN2 are presented in Figure 3 and Table 2 . In the subgroup of women <30 years (n=221; 30 ≥CIN3, 39 CIN2 and 152 ≤CIN1), the ≥CIN3 sensitivity of FAM19A4 methylation analysis was significantly lower compared to that of cytology (50.0% versus 86.7%; ratio 0.58; 95%CI:0.40-0.83; Table 1 ), whereas its specificity was significantly higher (81.7% versus 52.4%; ratio 1.56; 95%CI:1.35-1.80; Table 1 ). In the subpopulation of women referred to the gynecologist because of non-cervix-related gynecological complaints (n=295; 26 ≥CIN3, 43 CIN2 and 226 ≤CIN1), the ≥CIN3 sensitivity of FAM19A4 methylation analysis did not differ significantly from cytology (61.5% versus 80.8%; ratio 0.76; 95%CI:0.55-1.05). Subsequent matched sample score testing was performed to evaluate non-inferiority, which could not be established (p=0.85). The specificity of FAM19A4 methylation analysis was significantly higher than that of cytology (73.2% versus 63.6%; ratio 1.15; 95%CI:1.03-1.28). Results for ≥CIN2 are presented in Table 2 .
DISCUSSION
This prospective multi-center cohort study shows that molecular analysis of FAM19A4 methylation is non-inferior to cytology with respect to sensitivity for ≥CIN3 (88.3% versus 85.0%) in hrHPV-positive women from an outpatient population, aged ≥30 years, at a significantly higher specificity (62.1% versus 47.6%), In women <30 years, an age category known to often harbor transient hrHPV infections 33, 34 , FAM19A4 methylation analysis had a poor ≥CIN3 sensitivity compared to cytology (50% versus 86.7%), but had a significantly higher specificity (81.7% versus 52.4%). To our knowledge, this study is the first to compare the clinical features of FAM19A4 methylation analysis to those of other commonly used tests for detecting cervical disease in a large cohort of women with hrHPV-positive cervical scrapes. Even under the setting of potential cytology bias, given that a part of women were included with a previously abnormal cytology test, the sensitivity of FAM19A4 methylation analysis reached non-inferiority to cytology in hrHPV-positive women aged ≥30 years. In notice of a cytology bias, we included in our study a subgroup analysis of women who visited the outpatient clinic for non-cervix-related complaints, in which ≥CIN3 sensitivity of FAM19A4 methylation analysis also did not differ significantly from cytology (61.5% versus 80.8%; ratio 0.76; 95%CI:0.55-1.05), although non-inferiority could not be established. In a subgroup analysis comprising HPV-positive women with normal cytology ≥30 years of age (data not shown), FAM19A4 methylation analysis reached a ≥CIN3 sensitivity of 77.8 (7/9; 95%CI: 50.6-100%) at 67.6% specificity (73/108; 95%CI: 58.8-76.4%). Despite the fact that data are based on relatively low numbers, these findings illustrate the value of FAM19A4 methylation analysis for HPV-positive women with normal cytology.
Previous research has outlined the high sensitivity of DNA methylation analysis for detecting CIN3 lesions with a long duration of existence (so-called advanced CIN3 which are expected to have a high short-term risk of progression to cancer) and cervical carcinoma 23, 35 , in contrast to cytology 1, 15, 23, 36 . In the present study, 50/57 (87.8%) women ≥30 years with CIN3 lesions tested positive by FAM19A4 methylation analysis and 48/57 (84.2%) by cytology. On the other hand, only 26/51 (51%) women with CIN2 were positive by FAM19A4 methylation analysis, whereas 45/54 (88.2%) of these women tested positive for cytology. These data underscore that a positive FAM19A4 methylation result is more likely to represent underlying CIN3 than CIN2, whereas cytology, in this outpatient population, has high sensitivities for both CIN2 and CIN3.
The overall high sensitivity of cytology in this cohort might be explained by the presence of cytology bias in this referral population and/or the prior knowledge of the HPV status of the scrapes at cytology reading. This probably results in easier classification of abnormal cytology 37, 38 . In an HPV-based screening program, only hrHPV-positive women will be triaged by cytology, so it is important to stay alert for potential overreferral. FAM19A4 methylation analysis can therefore be an adequate alternative triage method, with a negative test result providing high reassurance of absence of advanced cervical disease and cancer 23 . Furthermore, as large variation exists in the quality of cytological screening amongst different countries, a more objective triage strategy of hrHPV-positive women in the future is preferable 39 . Among many previously described methylation markers 1, 40 , FAM19A4 has shown to efficiently detect virtually all cervical carcinomas and advanced CIN3 lesions 23 . In pilot studies, FAM19A4 methylation analysis appeared to perform well on cervical scrapes, which had been collected immediately prior to colposcopy. This is remarkable, as this sampling procedure has been shown to compromise performance of a previously validated methylation marker panel, i.e., CADM1/MAL, in a cross-sectional cohort 41 . The decrease in marker performance was likely related to more cautious brushing of the cervix (to prevent bleeding) and therefore lower abnormal cell counts in the resulting cervical scrapes 41 . In the current study, we found that the clinical performance of FAM19A4 methylation was not influenced by the sampling method of the cervical scrape (whether it was collected in a separate event or immediately prior to colposcopy). Another important finding of our research was the significant influence of age on FAM19A4 methylation positivity. This finding is in line with Hansel et al. 42 , who have described the detection of only 5/14 ≥CIN3 in women <30 years versus 8/9 ≥CIN3 in women ≥30 years using a methylation five-marker panel. However, Hesselink et al. 16 did not find a correlation of methylation with age using a bi-marker panel. The latter might be explained by the limited number of women <30 years included in that study. Our study included 287 women <30 years, giving a more representative view on the correlation between age and DNA methylation in detection of ≥CIN2/3. Although hrHPV prevalence in young women is known to be high, most infections are transient and most lesions regress spontaneously 34, 43, 44 , contributing to a very low cancer incidence in this age group 45 . Screening these young women by cytology would lead to high ≥CIN2/3 sensitivities, yet likely at the cost of detecting many regressing CIN2 and a number of early CIN3 lesions, leading to significant over-referral and -treatment. Although testing hrHPV-positive young women by FAM19A4 methylation analysis would result in a lower sensitivity for ≥CIN2/3 than cytology, it likely reassures against advanced CIN lesions and cervical cancer at a substantially higher specificity. If validated in an independent study, this hypothesis may form the basis of an interesting management strategy for young hrHPV-positive women visiting a gynecological outpatient clinic, given possible treatment morbidity such as cervical insufficiency, and associated risk for pre-term delivery [46] [47] [48] . The broad age range of the population provides insight in the performance of this molecular marker in younger women. A limitation of our study might be that the age categorization used in this study (≥30 years versus <30 years) is based on the starting age at which women in the Netherlands are invited for cervical screening (i.e., 30 years). However, several Western countries start screening at an earlier age. In the USA, the FDA has approved an HPV test for use as a first-line primary cervical cancer screening test for women of ≥25 years 49, 50 . Interestingly, in hrHPV-positive women in the age category ≥25 years (Supplementary Figure 1) , the performance of FAM19A4 methylation analysis was similar to the performance in women aged ≥30 years. Due to the selection of an outpatient population, one has to realize that the translation of our results into screening settings should be handled with care. Furthermore, the fact that 8% of FAM19A4 methylation analyses yielded an invalid test result is relevant. We found that the majority (89.5%) of these invalid tests were done on cervical scrapes taken directly prior to colposcopy. As mentioned above, more cautious scraping by the physician (to ascertain adequate colposcopic imaging) may have resulted in insufficient cell numbers in these cervical scrapes, and associated low DNA concentrations, which may contribute to invalid test results. In conclusion, this study showed that promoter methylation analysis of FAM19A4 is an objective, molecular marker that performs at least non-inferior to cytology for the detection of ≥CIN3 lesions in hrHPV-positive cervical scrapes from a gynecological outpatient population (aged ≥30 years) at a significantly higher specificity. Table 3B : Referral reason as a covariate of the performance of cytology. The odds ratios represent the odds of a positive cytology result in women referred to the gynecologist because of abnormal cytology relative to women referred for noncervix-related complaints (stratified by histological endpoint). 
TABLES
